Screening assays for binding antagonists of the AMD-associated variant of factor H (H384)
US7829301B2 · kind B2 · utility
0Cited by
0References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 10, 2007 |
| Grant date | Nov 9, 2010 |
| Priority date | — |
| Expiry date | Dec 3, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/02
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention relates to identifying agents which have the ability to preferentially inhibit binding to targets such as heparin of the H384 allotypic variant of human complement Factor H, the allotypic variant associated with age-related macular degeneration (AMD), and the non-disease associated form of the same factor (Y384). The targets of interest show differential binding of the two allotypic variants and antagonists thus identified are of interest in developing treatments for AMD.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.